MAPK drugs restore TSHR in aggressive thyroid tumors, helping CAR-T cell therapy see and control solid tumors again.
|Videos|November 3, 2017
Dr. Sacco on Upfront Treatments for Head and Neck Cancer
Author(s)Assuntina G. Sacco, MD
Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses upfront treatment for patients with head and neck cancer.
Advertisement
Data suggests that higher-dose cisplatin is superior to weekly-dose regarding local regional control. There is a trend to improved disease-free survival and overall survival, however further research is needed.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
4
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
5